The following are the primary outcomes to be measured : ( @ ) the trajectories of the left ventricular ejection fraction in the follow-up period ; ( @ ) reduction of heart disease progression rates , with progression defined as a @ % decrease in left ventricular ejection fraction ; and ( @ ) rate of hospital admissions attributable to dysrhythmia , heart failure or stroke due to Chagas disease .